Other substances

Influenza vaccine

Inactivated trivalent influenza vaccine

Phase of research

Potential treatment - clinical evidence

How it helps

Vaccine

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
22
 AI-suggested references
12
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
Influenza Vaccination and COVID19 Mortality in the USA
Preprint 		Patients

 results suggest a potential protective effect of the influenza vaccine on COVID-19 mortality in the elderly population

 Jun/26/2020
Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil
Preprint 		Patients

 patients who received a recent influenza vaccine experienced lower odds of needing intensive care treatment and invasive respiratory suppory, and of death

 Jul/01/2020

AI-suggested references

Link Publication date
Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
Feb/06/2021
Hesitancy of Arab Healthcare Workers towards COVID-19 Vaccination: A Large-Scale Multinational Study.
Nov/25/2021
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
Apr/15/2022
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged >=65 years: a phase 2, randomised, open-label study
Feb/25/2022
The Influenza Vaccine May Protect Pregnant and Postpartum Women against Severe COVID-19
Jan/28/2022
Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients
Aug/03/2021
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
Sep/04/2022
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial
Jan/25/2021
A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
Dec/15/2021
Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-alpha inhibitors
Nov/18/2021
Impact of the influenza vaccine on COVID-19 infection rates and severity
Nov/19/2020
Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.
Nov/21/2020
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Mar/14/2022
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
Feb/12/2022
Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
Sep/11/2021
Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology
Feb/08/2022
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine**
Mar/11/2021
SARS-CoV-2 does not replicate in embryonated hen's eggs or in MDCK cell lines
Apr/29/2020
Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers
Dec/28/2021
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Aug/26/2021
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
Mar/30/2020
Effect of influenza vaccine on COVID-19 mortality: a retrospective study
Apr/12/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04984408 Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Not yet recruiting Phase 3 Oct/01/2021 Sep/30/2024
  • Alternative id - IVI-ECOVA-01
  • Interventions - Biological: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|Biological: influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 8825
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Protection conferred by BBIBP-CorV vaccine against any COVID-19 disease|Incidence of solicited adverse events, unsolicited adverse events and serious adverse events and adverse events of special interest (AESIs)|Protection conferred by BBIBP-CorV vaccine against symptomatic COVID-19 disease|Protection conferred by BBIBP-CorV vaccine against asymptomatic SARS-CoV-2 infection (any SARS-CoV-2 variant)|Protection conferred by BBIBP-CorV vaccine against severe COVID-19 disease and COVID-19 associated death|Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in subset of participants|Incidence of solicited adverse events, unsolicited adverse events and serious adverse events and adverse events of special interest (AESIs) in HIV-infected adults|Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in subset of participants in HIV-infected adults|SARS-CoV-2 sequence variants among HIV-infected and HIV-uninfected, BBIBP-CorV vaccine and placebo recipients|Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody in the Arm 3 as compared to Arm 1 and 2 (subset participants).|Incidence of adverse event (AE) after each vaccination, serious adverse event (SAE), adverse events of special interests (AESIs) according to Brighton Collaboration list for COVID-19 vaccine studies among participants receiving the study vaccines.|Humoral and cellular immune responses of HIV-infected participants as compared to HIV-uninfected vaccine and control arms (subset participants of Arms 1 and 2)|Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) of anti-SARS-CoV-2 neutralizing antibody following booster dose of BBIBP-CorV vaccine|Incidence of solicited adverse events, unsolicited adverse events and serious adverse events and adverse events of special interest (AESIs) among HIV uninfected adults.
NCT05091307 A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults Recruiting Phase 3 Nov/02/2021 Aug/31/2022
  • Alternative id - CR109083|2021-003953-43|VAC31518COV3005
  • Interventions - Biological: Ad26.COV2.S|Other: Placebo|Biological: Influenza Vaccine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Fiel Family and Sports Medicine Clinical Research Advantage, Tempe, Arizona, United States|Altasciences Inc., Cypress, California, United States|Ark Clinical Research, Long Beach, California, United States|Wr-McCr, Llc, San Diego, California, United States|Clinical Research of South Florida, an AMR Company, Coral Gables, Florida, United States|AMR Fort Myers Clinical Physiology Associates, an AMR company, Fort Myers, Florida, United States|Office of Emilio Mantero-Atienza, MD, Miami, Florida, United States|University of Miami Health System, Miami, Florida, United States|Premier Research Associate, Inc, Miami, Florida, United States|Medisphere Medical Research Center, Llc, Evansville, Indiana, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States|I.D. Care, Inc., Hillsborough, New Jersey, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Coastal Carolina Research Center, North Charleston, South Carolina, United States|Ventavia Research Group, LLC, Keller, Texas, United States|Research Your Health, Plano, Texas, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|Anima, Alken, Belgium|Institute of Tropical Medicine Antwerp, Antwerpen, Belgium|Center for Vaccinology (CEVAC), Gent, Belgium|Clinical Pharmacology Unit, Merksem, Belgium|Private Practice RESPISOM Namur, Namur, Belgium|Universiteit Antwerpen, Wilrijk, Belgium|Centrum Medyczne PRATIA Bydgoszcz, Bydgoszcz, Poland|Centrum Medyczne Synexus, Częstochowa, Poland|Centrum Medyczne Synexus, Gdansk, Poland|Gdanskie Centrum Zdrowia, Gdansk, Poland|Synexus Scm Sp. Z o.o. Oddzial Gdynia, Gdynia, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Synexus Polska Sp. z o.o., Lodz, Poland|Centrum Medyczne Synexus, Poznań, Poland|Centrum Medyczne Pratia Poznan, Skorzewo, Poland|Centrum Medyczne Synexus, Warszawa, Poland|Centrum Medyczne Synexus, Wroclaw, Poland
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 1680
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Groups 1 and 2: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Against each of the 4 Influenza Vaccine Strains at 28 Days After the Administration of a Seasonal Quadrivalent Standard-dose Influenza Vaccine|Groups 3 and 4: GMT of HI Antibody Against each of the 4 Influenza Vaccine Strains at 28 Days After the Administration of a Seasonal Quadrivalent High-dose Influenza Vaccine|Groups 1 and 2: Spiked-Enzyme-linked Immunosorbent Assay (S-ELISA) Geometric Mean Concentrations (GMCs) 28 Days After the Administration of Ad26.COV2.S Vaccine|Groups 3 and 4: S-ELISA GMCs 28 Days After the Administration of Ad26.COV2.S Vaccine|Groups 1, 2, 3, and 4: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each vaccination|Groups 1, 2, 3, and 4: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination|Groups 1, 2, 3, and 4: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination|Groups 1, 2, 3, and 4: Number of Participants with Serious Adverse Events (SAEs)|Groups 1, 2, 3, and 4: Number of Participants with Medically-attended Adverse Events (MAAEs)|Groups 1, 2, 3, and 4: Number of Participants with Adverse Events of Special Interest (AESIs)|Groups 1, 2, 3, and 4: Number of Participants with AEs Leading to Withdrawal from the Study|Groups 1, 2, 3, and 4: Number of Naive Participants with Antibody GMC as Assessed by S-ELISA 28 Days After the Administration of Ad26.COV2.S|Groups 1, 2, 3, and 4: Percentage of Participants with Seroconversion for each of the 4 Influenza Vaccine Strains at 28 Days After the Administration of a Seasonal Quadrivalent (High-dose and Standard-dose) Influenza Vaccine|Groups 1, 2, 3, and 4: Percentage of Participants with Seroprotection for each of the 4 Influenza Vaccine Strains as HI titer >= 1:40 at 28 Days After the Administration of a Seasonal Quadrivalent (High-dose and Standard-dose) Influenza Vaccine
NCT04583995 A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom Active, not recruiting Phase 3 Nov/28/2020 Jan/28/2023
  • Alternative id - 2019nCoV-302
  • Interventions - Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant|Other: Placebo|Biological: Licensed seasonal influenza vaccine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Belfast Health and Social Care Trust (BHSCT) (Site UK011), Belfast, Antrim, United Kingdom|Synexus Midlands Clinical Research Centre (Site UK024), Edgbaston, Birmingham, United Kingdom|The Royal Cornwall Hospitals NHS Trust (Site UK036), Truro, Cornwall, United Kingdom|Royal Devon and Exeter Hospital (Site UK013), Exeter, Devon, United Kingdom|"Maidstone Hospital - Central Research and Development Office Above Breast Care Centre - 1st Floor" (Site UK028), Maidstone, Kent, United Kingdom|Queen Elizabeth University Hospital (Site UK008), Glasgow, Lanarkshire, United Kingdom|Blackpool Teaching Hospitals (Site UK010), Blackpool, Lancashire, United Kingdom|Salford Hospital (Site UK030), Oldham, Lancashire, United Kingdom|Synexus Merseyside Clinical Research Centre (Site UK026), Waterloo, Liverpool, United Kingdom|Royal Free (Site UK012), Hampstead, London, United Kingdom|St. George's University Hospitals NHS Foundation Trust Clinical Research Facility (Site UK001), Tooting, London, United Kingdom|North Wales Clinical Research Centre (NWCRC) (Site UK027), Wrexham, North Wales, United Kingdom|Lakeside Healthcare, Lakeside Surgery (Site UK005), Corby, Northants, United Kingdom|Warneford Hospital (Site UK016), Oxford, Oxfordshire, United Kingdom|Aberdeen Royal Infirmary (Site UK007), Foresterhill, Aberdeen, United Kingdom|Bradford Teaching Hospitals NHS Trust (Site UK018), Bradford, United Kingdom|Synexus Wales Clinical Research Centre (Site UK025), Cardiff, United Kingdom|Synexus Lancashire Clinical Research Centre (Site UK022), Chorley, United Kingdom|Colchester Hospital (Site UK034), Colchester, United Kingdom|AES - Glasgow (Site UK033), Glasgow, United Kingdom|University Hartlepool Hospital (Site UK021), Hartlepool, United Kingdom|Synexus Hexham Clinical Research Centre (Site UK023), Hexham, United Kingdom|Royal Lancaster Infirmary (Site UK029), Lancaster, United Kingdom|Research & Innovation Centre, St. James's University Hospital (Site UK019), Leeds, United Kingdom|St. Thomas' Hospital (Site UK020), London, United Kingdom|Chelsea & Westminster NHS Foundation Trust (Site UK006), London, United Kingdom|AES - Synexus Manchester (Site UK032), Manchester, United Kingdom|Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk and Norwich University Hospital (Site UK015), Norwich, United Kingdom|Wansford and Kingscliffe Practice (Site UK035), Peterborough, United Kingdom|AES - Synexus Thames Valley (Site UK031), Reading, United Kingdom|University Hospital Southampton NHS Foundation Trust (UHS) (Site UK014), Southampton, United Kingdom|Midlands Partnership NHS Foundation Trust Headquarters (Site UK017), Stafford, United Kingdom|Stockport NHS Foundation Trust (Site UK009), Stockport, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 16753
  • Age - 18 Years to 84 Years   (Adult, Older Adult)
  • Outcome measures - Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)|Participants with Symptomatic Moderate or Severe COVID-19|Participants with Symptomatic Severe COVID-19|Participants with Symptomatic Mild, Moderate, or Severe COVID-19 Regardless of Baseline Serostatus|Participants with Asymptomatic or Symptomatic COVID-19|Participants with COVID-19 requiring Hospitalization, Intensive Care Unit (ICU), or Mechanical Ventilation|Participants with Symptomatic Mild COVID-19|Serum IgG Antibody Levels at Multiple Time Points Expressed as Geometric Mean ELISA Units (GMEUs)|Participants with Serious Adverse Events (SAEs)|Participants with Medically Attended Adverse Events (MAAEs) Related to Study Vaccination|Participants with Adverse Events of Special Interest (AESIs)|Participants with Solicited Local and Systemic Adverse Events (AEs)|Participants with All MAAEs Through Day 35|Participants with Unsolicited AEs Through Day 49
NCT04833101 Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine Active, not recruiting Phase 4 Apr/07/2021 Dec/15/2021
  • Alternative id - JSVCT115
  • Interventions - Biological: recombinant Ad5 vectored COVID-19 vaccine|Biological: RBD-based protein subunit vaccine (ZF2001) against COVID-19|Biological: trivalent split influenza vaccine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 120
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of solicited adverse events within 7 days after vaccination.|GMT of neutralizing antibodies against live SARS-CoV-2 virus at Day 14 after the booster vaccination.|Incidence of adverse reactions within 28 days after vaccination.|Incidence of adverse events within 28 days after vaccination.|Incidence of unsolicited AE within 28 days after vaccination.|Incidence of serious adverse events(SAE) from the first dose to the 6 months after completing the last dose of vaccination.|GMT of binding antibodies against SARS-CoV-2 S and RBD protein measured by ELISA at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.|Proportion of the participants with at least a four-fold increase of the binding antibodies against SARS-CoV-2 S and RBD protein at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.|Fold increase of binding antibodies against SARS-CoV-2 S and RBD protein at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.|GMT of neutralizing antibodies against live SARS-CoV-2 virus at day 28 after the second vaccination, and day 14, month 6 after the third vaccination|Proportion of the participants with at least a four-fold increase of neutralizing antibodies against live SARS-CoV-2 virus at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.|Fold increase of neutralizing antibodies against live SARS-CoV-2 virus at day 14, day 28 after the second vaccination and day 14, month 6 after the third vaccination.
NCT04801888 Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine Completed Phase 4 Mar/23/2021 May/28/2021
  • Alternative id - PRO-QINF-4001
  • Interventions - Biological: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|Biological: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Kaihua county Center for Disease Control and Prevention, Quzhou, Zhejiang, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 480
  • Age - 18 Years to 59 Years   (Adult)
  • Outcome measures - Safety index-incidence of adverse reactions within 7 days after each dose|Immunogenicity index-seroconversion rates of neutralizing antibody against SARS-CoV-2|Safety index-incidence of adverse reactions within 56 days after the first dose vaccination|Safety index-incidence of serious adverse events|Immunogenicity index-seropositive rates of neutralizing antibody against SARS-CoV-2|Immunogenicity index-geometric mean titer (GMT) of neutralizing antibody against SARS-CoV-2|Immunogenicity index-geometric mean ratio (GMR) of neutralizing antibody against SARS-CoV-2|Immunogenicity index-seroconversion rates of influenza HI antibodies|Immunogenicity index-protective rates of influenza HI antibodies|Immunogenicity index-geometric mean titer (GMT) of influenza HI antibodies|Immunogenicity index-geometric mean ratio (GMR) of influenza HI antibodies
NCT05107375 Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine Recruiting Phase 3 Sep/03/2021 Mar/04/2022
  • Alternative id - IIT-LKM-2021-NCV01
  • Interventions - Biological: Tetravalent influenza virus lysis vaccine|Biological: Recombinant new coronavirus vaccine (CHO cell) group
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Primary endpoint:|Secondary endpoint:
NCT04025580 Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine Suspended Phase 2 Oct/02/2019 Dec/31/2025
  • Alternative id - 190126|19-I-0126
  • Interventions - Biological: Flucelvax|Biological: Fluvirin|Biological: Fluzone High Dose
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - National Institutes of Health Clinical Center, Bethesda, Maryland, United States
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  • Enrollment - 90
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Microneutralization titers
NCT04969276 Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine Completed Phase 2 Jul/16/2021 Feb/08/2022
  • Alternative id - QHD00028|U1111-1266-7472
  • Interventions - Biological: Quadrivalent Inactivated Influenza High Dose|Biological: COVID-19 mRNA Vaccine (nucleoside modified)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Investigational Site Number :8400003, Glendale, Arizona, United States|Investigational Site Number :8400006, San Diego, California, United States|Investigational Site Number :8400004, Vista, California, United States|Investigational Site Number :8400005, Centennial, Colorado, United States|Investigational Site Number :8400001, Peoria, Illinois, United States|Investigational Site Number :8400002, Austin, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 278
  • Age - 65 Years and older   (Older Adult)
  • Outcome measures - Number of participants with immediate adverse events (AEs)|Number of participants with solicited injection site reactions or systemic reactions|Number of participants with unsolicited AEs|Number of participants with serious adverse events (SAEs) and Adverse Events of Special Interest (AESIs)|Number of participants with medically attended adverse events (MAAE)s|Hemagglutination inhibition (HAI) individual titer|Individual HAI titers ratio D22/D01|Number of participants with influenza vaccine antibody titer ≥ 10|Number of participants with influenza vaccine antibody titer ≥ 40|Number of participants with seroconversion|Individual anti-S binding IgG concentration|Individual anti-S binding IgG concentration ratio D22/D01|2-fold-rise in anti-S binding IgG concentration|4-fold-rise in anti-S binding IgG concentration
NCT04993365 Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With Quadrivalent Influenza Vaccine And 23-valent Pneumococcal Polysaccharide Vaccine Not yet recruiting Phase 4 Sep/01/2021 Aug/01/2022
  • Alternative id - PRO-nCOV-4002
  • Interventions - Biological: Experimental Group1|Biological: Experimental Group 2|Biological: Experimental Group 3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Huaiyin Center for Disease Control and Prevention, Huai'an, Jiangsu, China|Binhai Center for Disease Control and Prevention, Yancheng, Jiangsu, China|Xiangshui Center for Disease Control and Prevention, Yancheng, Jiangsu, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 1320
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Immunogenicity index of GMT of the neutralizing antibody|Immunogenicity indexes of GMT of HI antibody for each of the 4 virus strains|Immunogenicity indexes of GMC of pneumococcal IgG antibody for the three serotypes (3, 19A and 19F)|Immunogenicity index of seroconversion rate of the neutralizing antibody|Immunogenicity index of seropositivity rate of the neutralizing antibody|Immunogenicity index of GMI of the neutralizing antibody|Immunogenicity indexes of seroconversion rate of HI antibody for each of the 4 virus strains|Immunogenicity indexes of seroprotection rate of HI antibody for each of the 4 virus strains|Immunogenicity indexes of GMI of HI antibody for each of the 4 virus strains|Immunogenicity indexes of seroconversion rate of pneumococcal IgG antibody for the three serotypes (3, 19A and 19F)|Immunogenicity indexes of GMI of pneumococcal IgG antibody for the three serotypes (3, 19A and 19F)|Immunogenicity indexes of seroconversion rate of pneumococcal IgG antibody for the three serotypes (1,2,4,5,6B,7F,8,9N、9V、10A 11A,12F,14,15B,17F,18C,20,22F,23F and 33F)|Immunogenicity indexes of GMC of pneumococcal IgG antibody for the three serotypes (1,2,4,5,6B,7F,8,9N、9V、10A 11A,12F,14,15B,17F,18C,20,22F,23F and 33F)|Immunogenicity indexes of GMI of pneumococcal IgG antibody for the three serotypes (1,2,4,5,6B,7F,8,9N、9V、10A 11A,12F,14,15B,17F,18C,20,22F,23F and 33F)|Safety index of incidence of the adverse reactions|Safety indexes of incidence of the serious adverse events and the adverse events of special interest
NCT04806529 An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older Withdrawn Phase 2|Phase 3 Dec/15/2020 Apr/09/2022
  • Alternative id - V451_07
  • Interventions - Drug: Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Drug: Comparator
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Primary endpoint - preventing first occurrence of virologically-confirmed (RT-PCR) symptomatic COVID-19 cases as defined by ECDC guidance|Co-primary endpoint - If successful, the co-primary measure of efficacy is preventing first-occurrence of symptomatic COVID-19 as defined by the US FDA guidance|Secondary endpoint #1 - preventing first occurrence of RT-PCR confirmed severe COVID-19|Secondary endpoint #2 - number of subjects hospitalized with RT-PCR-confirmed COVID-19 versus placebo|Secondary endpoint #3- number of subjects admitted to ICU with RT-PCR-confirmed COVID-19 versus placebo
NCT04848467 COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older Withdrawn Phase 3 Oct/01/2021 Nov/15/2022
  • Alternative id - 21819
  • Interventions - Biological: SARS-CoV-2 mRNA Vaccine (CVnCoV)|Biological: Quadrivalent influenza vaccine (QIV)|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 0
  • Age - 60 Years and older   (Adult, Older Adult)
  • Outcome measures - Antibody titers for SARS-CoV-2 receptor binding domain (RBD)|Hemagglutination inhibition (HI) titers for each of the 4 strains|Number of participants seroconverting for SARS-CoV- 2 spike protein antibodies|SARS-CoV-2 spike protein-specific antibody levels in serum|Number of participants seroconverting for SARS-CoV- 2 neutralizing antibodies|SARS-CoV-2 neutralizing antibody levels in serum|Number of participants with seroprotection for serum antibodies against the 4 influenza vaccine strains|Number of participants seroconverting for serum antibodies against the 4 influenza vaccine strains|Serum antibody titers against the 4 influenza vaccine strains|Number of participants with solicited local adverse events (AEs) of CVnCoV vaccine|Number of participants with solicited systemic AEs|Number of participants with unsolicited AEs|Number of participants with serious adverse event (SAEs)|Number of participants with adverse event of special interest (AESIs)
NCT05047770 A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine Active, not recruiting Phase 3 Oct/07/2021 Jul/27/2022
  • Alternative id - 217670
  • Interventions - Biological: HZ/su|Combination Product: Flu D-QIV|Biological: mRNA-1273
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - GSK Investigational Site, Tomball, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 1546
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Anti-glycoprotein E (gE) antibody concentrations expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd groups, and between-group ratios|Anti-S protein antibody concentrations expressed as GMCs in HZ/suSeq and HZ/suCoAd groups, and between-group ratios|Anti-hemagglutinin inhibition (HI) antibody titers expressed as Geometric Mean Titers (GMTs) against the 4 influenza strains in Flu D-QIV vaccine in FluD-QIVSeq and FluD-QIVCoAd groups, and between-group ratios|Anti-S protein antibody concentrations expressed as GMCs in FluD-QIVSeq and FluD-QIVCoAd groups, and between-group ratios|Percentage of participants seroconverted for anti-HI antibodies against the 4 influenza strains in FluD-QIVSeq and FluD-QIVCoAd groups, and between-group differences|Percentage of participants seropositive for anti-gE antibodies in HZ/suSeq and HZ/suCoAd groups|Anti-gE antibody concentrations expressed as GMCs in HZ/suSeq and HZ/suCoAd groups|Percentage of participants with a vaccine response for anti-gE in HZ/suSeq and HZ/suCoAd groups|Mean geometric increase (MGI) for anti-gE in HZ/suSeq and HZ/suCoAd groups|Anti-S protein antibody concentrations expressed as GMCs in HZ/suSeq and HZ/suCoAd groups|Anti-S protein antibody concentrations expressed as GMCs in FluD-QIVSeq and FluD-QIVCoAd groups|MGI for anti-S protein in HZ/suSeq and HZ/suCoAd groups|MGI for anti-S protein in FluD-QIVSeq and FluD-QIVCoAd groups|Anti-HI antibody titers expressed as GMTs against the 4 influenza strains in Flu D-QIV vaccine in FluD-QIVSeq and FluD-QIVCoAd groups|Percentage of participants seroprotected for anti-HI against the 4 influenza strains in FluD-QIVSeq and FluD-QIVCoAd groups|Percentage of participants seropositive for anti-HI against the 4 influenza strains in FluD-QIVSeq and FluD-QIVCoAd groups|MGI for anti-HI against the 4 influenza strains in FluD-QIVSeq and FluD-QIVCoAd groups|Percentage of participants seroconverted for anti-HI against the 4 influenza strains in FluD-QIVSeq and FluD-QIVCoAd groups, per age strata|Percentage of participants in HZ/suSeq and HZ/suCoAd groups reporting solicited local adverse events|Percentage of participants in FluD-QIVSeq and FluD-QIVCoAd groups reporting solicited local adverse events|Percentage of participants in HZ/suSeq and HZ/suCoAd groups reporting solicited systemic adverse events|Percentage of participants in FluD-QIVSeq and FluD-QIVCoAd groups reporting solicited systemic adverse events|Percentage of participants in HZ/suSeq and HZ/suCoAd groups reporting unsolicited adverse events|Percentage of participants in FluD-QIVSeq and FluD-QIVCoAd groups reporting unsolicited adverse events|Percentage of participants reporting serious adverse events (SAEs)|Percentage of participants reporting SAEs|Percentage of participants in HZ/suSeq and HZ/suCoAd groups reporting potential immune mediated diseases (pIMDs)|Percentage of participants in HZ/suSeq and HZ/suCoAd groups reporting pIMDs|Percentage of participants reporting adverse events of special interest (AESIs)|Percentage of participants reporting AESIs|Percentage of participants in HZ/suSeq and HZ/suCoAd groups reporting clinically suspected HZ episodes|Percentage of participants meeting case definitions of COVID-19
Export (.csv)